Navigation Links
Stress may make you itch
Date:10/26/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2012)... Athens, Ga. The rate at which the rabies ... ecological traits of its hosts, according to researchers at ... Control and Prevention and Katholieke Universiteit Leuven in Belgium. ... PLoS Pathogens , found that the host,s geographical location ... of evolution. Rabies viruses in tropical and sub-tropical bat ...
(Date:5/18/2012)... everyday life, we use gasoline, diesel, plastics, rubbers, ... oil through petrochemical refinery processes. However, this is ... fossil resources. Furthermore, our world is facing problems ... due to the increasing use of fossil resources. ... use of renewable non-food biomass for the production ...
(Date:5/18/2012)... the winners of their 6th Annual Research Awards ... the very best research that has been made ... guests attended the prestigious ceremony including leading researchers, ... world. , The winners were selected by ... journals which published more than 18,000 peer-reviewed open ...
Breaking Biology News(10 mins):Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3Production of chemicals without petroleum 2BioMed Central announces winners of 6th Annual Research Awards 2Pharmacists Offer Guidance on Top Over The Counter Medications 16616 1Pharmacists Offer Guidance on Top Over The Counter Medications 16616 2Pharmacists Offer Guidance on Top Over The Counter Medications 16616 3Researchers report widespread use of medications among pregnant women 81301 1Researchers report widespread use of medications among pregnant women 81301 2Rice born detector finds heaviest antimatter 18956 1Rice born detector finds heaviest antimatter 18956 2Rice born detector finds heaviest antimatter 18956 3
... Metabolic syndrome, a collection of related abnormalities like ... a major risk for developing heart disease and ... cholesterol (familial hyperlipidemia or FH) can be especially ... found that blocking the enzyme stearoyl-CoA desaturase-1 (SCD1), ...
... bioengineer Jennifer West is being recognized today with one ... O,Donnell Award from The Academy of Medicine, Engineering and ... for excellence in medical, scientific and engineering research, include ... West, a pioneer in the field of biomaterials engineering, ...
... the Stanford University Program in Biodesign have released ... requirements of medical device regulation in the United ... 2007 issue of the Journal of Medical Devices, ... versus pharmaceuticals and underscores the complexity of the ...
Other Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3Stanford researchers publish review of US medical device regulation 2Stanford researchers publish review of US medical device regulation 3
(Date:5/16/2012)... Calif., May 16, 2012  Questcor Pharmaceuticals, Inc. ... its Board of Directors has increased the Company,s ... 5 million shares. Since the beginning ... to shareholders through the repurchase of approximately 19.2 ... of its shares as of the commencement of ...
(Date:5/15/2012)... Journal of Visualized Experiments ) will publish two articles ... Reduction Agency (DTRA). JoVE is proud ... Schafmeister and State University of New York Buffalo,s Dr. ... support of scientists conducting research for DTRA has significant ... defense threats. DTRA exists to safeguard America and its ...
(Date:5/15/2012)... May 15, 2012  OrbusNeich today announced that 12-month ... and safety outcomes involving the use of the company,s ... ® Liberte ® paclitaxel-eluting stent. The data ... I at the Lukaskrankenhaus in Neuss, Germany, at EuroPCR ... set, the clinically driven target lesion failure (TLF) rate ...
(Date:5/15/2012)... Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation ... trials, is pleased to announce today that the expertise ... subsidiary, Antigen Express, Inc., has been expanded by the ... research and immuno-therapeutic treatments of breast cancer: ... University School of Medicine Melvin and Bren ...
Breaking Biology Technology:Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5JoVE partners with US government to publish cutting-edge defense research 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 3OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 4Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 2Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 3Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 4
... 8 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... the leading plasma-based pharmaceutical companies,in the People,s Republic ... present at the upcoming SIG Second Annual Beijing ... the Grand Hyatt Beijing Hotel in Beijing., ...
... 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, - Safety and ... ... Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort of a,4-week Phase ...
... and DUBLIN, Ireland, Sept. 8 /PRNewswire-FirstCall/,-- Concuity, ... TTPA ) and a leading,provider of contract ... HFMA") and services, today announced that Valley ... Compliance suite to more,accurately calculate payments from ...
Other Biology Technology:China Biologic Products to Present at the SIG Beijing Management Summit 2China Biologic Products to Present at the SIG Beijing Management Summit 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 3Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 4